Loading...
XNAS
CSBR
Market cap69mUSD
Oct 08, Last price  
4.98USD
1D
2.05%
1Q
-14.43%
Jan 2017
96.84%
Name

Champions Oncology Inc

Chart & performance

D1W1MN
XNAS:CSBR chart
P/E
—
P/S
1.16
EPS
—
Div yield, %
—
Shrs. gr., 5y
-1.04%
Rev. gr., 5y
7.68%
Revenues
59m
+4.36%
01,400,0003,710,0004,893,0006,882,0007,149,0008,323,00011,550,0008,863,00011,182,00015,411,00020,241,00027,067,00032,123,00041,040,00049,109,00053,870,00050,155,00056,944,00059,425,000
Net income
-1m
L
-170,058-411,000-2,242,000-2,923,000-3,802,000-8,661,000-6,330,000-7,406,000-13,140,000-10,446,000-6,884,000-1,476,000128,000-2,093,000362,000548,000-5,335,000-7,276,0004,701,000-1,175,000
CFO
-4m
L
-78,475792,404-888,000-2,100,000-54,000-5,227,000-4,262,000-3,433,000-9,630,000-6,452,000-2,840,000-1,226,0001,862,0002,905,000-1,681,0006,497,0003,955,000-6,137,0007,386,000-4,472,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

Key people

Joel Ackerman
Chairman of the Board · since 2017
David Miller
Chief Financial Officer · since 2017
Ronnie Morris
Chief Financial Officer, Director · since 2017
Philip Breitfeld
Chief Strategic and Innovation Officer, Director · since 2016
David Sidransky
Lead Independent Director · since 2017
Abba David Poliakoff
Independent Director · since 2008
Scott R. Tobin
Independent Director · since 2011
URL
https://championsoncology.com
IPO date
Nov 30, 1988
Employees
230
Domiciled in
US
Incorporated in
US
Legal address
C/O Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
1 University Plaza
Suite 307
Hackensack, NJ 07601
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT